AUSTRALASIA

We supply a diversified portfolio of branded prescription, OTC, consumer and
infant nutritional products into Australia and New Zealand. We are one of the
largest manufacturers in Australia and our manufacturing site in Melbourne
produces certain tablets, liquids and semi-solids.

Key Countries

Australia
New Zealand

Contribution to Group revenue

Revenue contribution - by therapeutic category

The Australian pharmaceutical sector was valued at AUD18,3 billion as at 30 June 2017 with volume growth of 8,2%.
Aspen is currently ranked 3rd by volume and 10th by value in the Australian pharmaceutical sector for the year ended 30 June 2017.
Almost one in six scripts written in Australia is for a product distributed by Aspen.

Source: June 2017 IMS

STATISTICS

Number of products launched:

2

(2016: 9)

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:

0 – 2 years

USD65 million

3 – 5 years

USD25 million

Number of product recalls:

3

(2016: 1)

Average staff turnover:

7,5%

(2016: 21,3%)

Number of work-related fatalities:

Nil

(2016: nil)

Number of permanent employees:

Revenue – R’billion	2017	2016 (CER)*	% change
Total	6,1	6,0	1
Commercial Pharmaceuticals	4,8	4,5	7
Anaesthetics	0,6	-	>100
High Potency & Cytotoxics	0,5	0,5	2
Other Commercial Pharmaceutical Brands	3,7	4,0	(9)
Nutritionals	0,8	1,0	(21)
Manufacturing-FDF	0,5	0,5	0

* Constant exchange rate: FY16 restated at FY17 average exchange rates.
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.